Fig. 1: Clinical overall response after HRC0202 infusion. | Cancer Gene Therapy

Fig. 1: Clinical overall response after HRC0202 infusion.

From: An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously

Fig. 1

The bar chart shows the clinical overall response and follow-up of patients after HRC0202 infusion. Each bar represents an individual patient and corresponding number. The different colors represent different clinical response. sCR stringent complete response, CR complete response, VGPR very good partial response, PR partial response, MR minimal response, SD stable disease, PD progressive disease.

Back to article page